Shola Olafuyi

Contact

• workRoom Room E2d Medical School Building
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work+44 115 82 30303
• Olusola.Olafuyi@nottingham.ac.uk

Biography

I am a passionate and highly motivated academic with research expertise in physiologically based pharmacokinetics (PBPK). I aspire to mentor and inspire the next generations of scientist.

I completed my BPharm degree in Pharmacy from University of Lagos, Nigeria and proceeded to gain clinical pharmacy experience as a pharmacist at the Chevron Nigeria Limited Hospital in Lagos and Reddington Multispecialist Hospital in Lagos for about 3 years.

I have an MSc. clinical pharmacy degree from the University of Strathclyde, Glasgow and I did my MSc project in the area of pharmacokinetics under the supervision of Dr Alison Thomson.

I have a PhD degree in physiologically based pharmacokinetics from Aston University which was obtained under the supervision of Dr Raj S.K Badhan and Prof Michael Coleman. My research involved the development of physiologically based pharmacokinetic models for antimalarial drugs used in special populations and was aimed at assessment of the pharmacokinetics of antimalarials in these population groups with the focus of understanding the pharmacokinetics of antimalarials and optimisation of antimalarial medication therapy.

I joined University of Nottingham in 2019 as an Assistant Professor in Pharmacology.

Expertise Summary

Pharmacokinetics, pharmacodynamics, PBPK modelling in special populations.

Teaching Summary

I am passionate about research inspired teaching excellence. I am currently a fellow of the HEA and hope to climb up the ranks in the future.

I am passionate about utilising current technologies to enhance students learning experience and facilitating learning in ways that promotes students engagement with the contents being learnt.

Recent Publications

• OLAFUYI, OLUSOLA, ABBASI, MOHAMMAD YASEEN and ALLEGAERT, KAREL, 2021. Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates-The impact of metabolising enzyme ontogeny and reduced cardiac output BIOPHARMACEUTICS & DRUG DISPOSITION. 42(9), 401-417
• OLAFUYI, OLUSOLA, PAREKH, NIKITA, WRIGHT, JACOB and KOENIG, JENNIFER, 2021. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? PHARMACOLOGY RESEARCH & PERSPECTIVES. 9(6),
• OLAFUYI O and BADHAN RKS, 2018. Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. Journal of pharmaceutical sciences. 108(1), 661-673
• BADHAN R, ZAKARIA Z and OLAFUYI O, 2018. The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options. Journal of pharmaceutical sciences. 107(8), 2236-2250

• View all publications

Future Research

1. Utilising PBPK modelling and simulation techniques to better understand the pharmacokinetics of several anti-infective drugs in sub-Saharan Africa (precisely, Western Africa) and propose how current drug therapy might be optimised or how new drug therapies might be effectively used. This involves ethical retrieval and generation of human physiological/biochemical data from subjects and using these data to develop virtual patients via in silico tools and using available or generated drug data to carryout pharmacokinetic modelling and simulations. This is important because the impact of physiological variabilities like CYP enzymes and transport protein polymorphisms, food intake, weight and blood biochemistry on the pharmacokinetics of several anti-infective agents in this ethnic groups is not well understood.
2. My PBPK modelling and simulation focuses on drugs used to treat tropical diseases like malaria and tuberculosis agents and drugs used to treat neglected tropical diseases. The patient groups of interest are young children (neonates and infants), older children and pregnant women.

• OLAFUYI, OLUSOLA, ABBASI, MOHAMMAD YASEEN and ALLEGAERT, KAREL, 2021. Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates-The impact of metabolising enzyme ontogeny and reduced cardiac output BIOPHARMACEUTICS & DRUG DISPOSITION. 42(9), 401-417
• OLAFUYI, OLUSOLA, PAREKH, NIKITA, WRIGHT, JACOB and KOENIG, JENNIFER, 2021. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? PHARMACOLOGY RESEARCH & PERSPECTIVES. 9(6),
• OLAFUYI O and BADHAN RKS, 2018. Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. Journal of pharmaceutical sciences. 108(1), 661-673
• BADHAN R, ZAKARIA Z and OLAFUYI O, 2018. The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options. Journal of pharmaceutical sciences. 107(8), 2236-2250
• OLAFUYI O, COLEMAN M and BADHAN RKS, 2017. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy. Biopharmaceutics & drug disposition. 38(8), 464-478
• OLAFUYI O, COLEMAN M and BADHAN RKS, 2017. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 106, 20-33
• Allegaert K, Abbasi MY, Michelet R, Olafuyi O. The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups-An Investigation Using Physiologically Based Pharmacokinetic Modelling. Pharmaceutics. 2022 Sep 16;14(9):1957. doi: 10.3390/pharmaceutics14091957. PMID: 36145705; PMCID: PMC9502676.
• Allegaert K, Abbasi MY, Annaert P, Olafuyi O. Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates. Expert Opin Drug Metab Toxicol. 2022 May;18(5):301-312. doi: 10.1080/17425255.2022.2099836. Epub 2022 Jul 15. PMID: 35796504.